105 related articles for article (PubMed ID: 36394458)
1. PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in Melanoma.
Mou K; Zhou Y; Mu X; Zhang J; Wang L; Ge R
Genet Test Mol Biomarkers; 2022 Nov; 26(11):503-511. PubMed ID: 36394458
[No Abstract] [Full Text] [Related]
2. PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Kupczyk P; Simiczyjew A; Marczuk J; Dratkiewicz E; Beberok A; Rok J; Pieniazek M; Biecek P; Nevozhay D; Slowikowski B; Chodaczek G; Wrzesniok D; Nowak D; Donizy P
Cells; 2021 Jan; 10(2):. PubMed ID: 33572647
[TBL] [Abstract][Full Text] [Related]
3. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
4. Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Donizy P; Wu CL; Mull J; Fujimoto M; Chłopik A; Peng Y; Shalin SC; Selim MA; Puig S; Fernandez-Figueras MT; Shea CR; Biernat W; Ryś J; Marszalek A; Hoang MP
Cells; 2020 May; 9(5):. PubMed ID: 32380691
[TBL] [Abstract][Full Text] [Related]
5. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
6. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E
Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Zhang Y; Huang J; Huang Y; Zhang S; Wu W; Long H; Duan X; Lai Y; Wu W
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179075
[TBL] [Abstract][Full Text] [Related]
8. Perillyle alcohol and Quercetin ameliorate monocrotaline-induced pulmonary artery hypertension in rats through PARP1-mediated miR-204 down-regulation and its downstream pathway.
Rajabi S; Najafipour H; Jafarinejad Farsangi S; Joukar S; Beik A; Iranpour M; Kordestani Z
BMC Complement Med Ther; 2020 Jul; 20(1):218. PubMed ID: 32660602
[TBL] [Abstract][Full Text] [Related]
9. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
11. NFATc2 is a potential therapeutic target in human melanoma.
Perotti V; Baldassari P; Bersani I; Molla A; Vegetti C; Tassi E; Dal Col J; Dolcetti R; Anichini A; Mortarini R
J Invest Dermatol; 2012 Nov; 132(11):2652-60. PubMed ID: 22718120
[TBL] [Abstract][Full Text] [Related]
12. The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer.
Malsy M; Graf B; Almstedt K
BMC Biochem; 2019 Jan; 20(1):2. PubMed ID: 30696421
[TBL] [Abstract][Full Text] [Related]
13. Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.
Chen B; Sun D; Qin X; Gao XH
Invest New Drugs; 2021 Aug; 39(4):928-948. PubMed ID: 33501609
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
15. Targeting of TRX2 by miR-330-3p in melanoma inhibits proliferation.
Yao Y; Zuo J; Wei Y
Biomed Pharmacother; 2018 Nov; 107():1020-1029. PubMed ID: 30257313
[TBL] [Abstract][Full Text] [Related]
16. Effect of NFATc2- and Sp1-mediated TNFalpha Regulation on the Proliferation and Migration Behavior of Pancreatic Cancer Cells.
Malsy M; Graf B; Bruendl E; Maier-Stocker C; Bundscherer A
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):706-711. PubMed ID: 38035702
[TBL] [Abstract][Full Text] [Related]
17. miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma.
Zuo J; Yu H; Xie P; Liu W; Wang K; Ni H
Gene; 2019 Aug; 710():233-239. PubMed ID: 31181312
[TBL] [Abstract][Full Text] [Related]
18. Identification of CXCL13 as an Immune-Related Biomarker Associated with Tumorigenesis and Prognosis in Cutaneous Melanoma Patients.
Si Z; Hu H
Med Sci Monit; 2021 Jul; 27():e932052. PubMed ID: 34247183
[TBL] [Abstract][Full Text] [Related]
19. Interaction between NFATc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t.
Malsy M; Graf B; Almstedt K
BMC Mol Biol; 2017 Aug; 18(1):20. PubMed ID: 28774282
[TBL] [Abstract][Full Text] [Related]
20. A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1.
Mitra A; Ghosh R
Mol Biol Rep; 2021 Aug; 48(8):5993-6005. PubMed ID: 34342816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
